GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » Return-on-Tangible-Asset

Winston Pharmaceuticals (Winston Pharmaceuticals) Return-on-Tangible-Asset : -148.59% (As of Mar. 2010)


View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Winston Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2010 was $-1.84 Mil. Winston Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2010 was $1.24 Mil. Therefore, Winston Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2010 was -148.59%.

The historical rank and industry rank for Winston Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

WPHM's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.6
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Winston Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Winston Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals Return-on-Tangible-Asset Chart

Winston Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Dec08 Dec09
Return-on-Tangible-Asset
-2,887.50 -5,812.50 -3.94 -99.50 -71.49

Winston Pharmaceuticals Quarterly Data
Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.98 -64.48 -97.81 -109.82 -148.59

Competitive Comparison of Winston Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Winston Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's Return-on-Tangible-Asset falls into.



Winston Pharmaceuticals Return-on-Tangible-Asset Calculation

Winston Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2009 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2009 )  (A: Dec. 2008 )(A: Dec. 2009 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2009 )  (A: Dec. 2008 )(A: Dec. 2009 )
=-2.655/( (5.769+1.659)/ 2 )
=-2.655/3.714
=-71.49 %

Winston Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2010 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2010 )  (Q: Dec. 2009 )(Q: Mar. 2010 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2010 )  (Q: Dec. 2009 )(Q: Mar. 2010 )
=-1.844/( (1.659+0.823)/ 2 )
=-1.844/1.241
=-148.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2010) net income data.


Winston Pharmaceuticals  (GREY:WPHM) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Winston Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061
Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser 10 percent owner 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver director, officer: Vice President 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg director, officer: Chief Financial Officer 2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel 10 percent owner 4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines